This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Pollock RF, Valentine WJ, THOMSEN TL, Nishimura H.Use of rapid-acting insulin aspart reduces costs and cardiovascular complications in type 2 diabetes when compared with human insulin. 45th Annual Meeting of the European Association for the Study of Diabetes: abstr. 891, 30 Sep 2009. Available from: URL: http://www.easd.org
Rights and permissions
About this article
Cite this article
Insulin aspart looks good for T2DM in Japan. Pharmacoecon. Outcomes News 589, 4 (2009). https://doi.org/10.2165/00151234-200905890-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905890-00007